Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival | SpringerLink
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival | SpringerLink
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | NEJM
Advances in Adjuvant Therapy For Cutaneous Melanoma: Implications for Clinical Practice | SCF - Skin Cancer Foundation Provider
Adjuvant Nivolumab Continues to Provide Superior Recurrence-Free
Cancers | Free Full-Text | Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival | Journal for ImmunoTherapy of Cancer
KEYNOTE-054 and CheckMate 238 Trial Updates
Long-term Analysis Shows Nivolumab Bests Ipilimumab in Resected
![ESMO 2020: [VIRTUAL] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16012149961918265235f709a14478d9.jpg "ESMO 2020: [VIRTUAL] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238")
ESMO 2020: [VIRTUAL] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | NEJM
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival
The Ever‐Evolving World of Melanoma Treatment
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma - ScienceDirect
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria - ScienceDirect
Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma | ESMO
OPDIVO® (nivolumab) Efficacy in the Adjuvant Treatment of Melanoma
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria - ScienceDirect
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better? | American Society of Clinical Oncology Educational Book
Pharmaceuticals | Free Full-Text | Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study
